Key Points
Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA)..
As per the latest enforcement report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market..
The drug in question is Mesalamine delayed-release capsule, indicated for the treatment of mild to moderate ulcerative colitis.The affected lot has been manufactured in a Mohali-based unit..
The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc..
You might be interested in
Sun Pharma recalls 55,000 bottles of generic drug from US market; here's why
10, Mar, 24The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report.
Zydus recalls over 55k bottles of generic drug in US
26, Mar, 23USFDA said the company is recalling the product due to failed impurities/ degradation specifications . An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine, it added. Zydus commenced the Class III recall on February 24 this year.
Revlimid: The Star Drug In U.S. For Indian Pharma Companies — BQ Exclusive
15, May, 23Revlimid is used to slow down or stop growth of cancer cells, besides treat anaemia patients with certain bone-marrow disorders.